RSS economic arm frowns on high cost of stents

Backs NPPA’s role in checking pharma, device prices

PT JYOTHI DATTA
Mumbai, January 25

The high cost of cardiac stents has come in for flak from the Swadeshi Jagran Manch (SJM), the economic wing of the RSS.

The SJM has red-flagged the exorbitant margins that push up stent prices for patients, even as it has supported the National Pharmaceutical Pricing Authority's (NPPA) watchdog role in the pharma and medical devices sectors.

In its letter to Prabhat Jha, Chairman of the Rajya Sabha’s Committee on Petitions, the SJM urged the Centre to not discriminate between the cost paid for a stent in a government-run institution and a private hospital.

“As an MP, you would be aware that the CGHS (Central Government Health Scheme) reimbursement rate for these stents is just ₹23,625. We would like to state that there should not be any discrimination between the costs reimbursed to government officials and the prices paid by the public,” the RSS thinktank said.

The SJM letter comes at a time when the NPPA has released different formulae to cap the price of cardiac stents.

There is “dichotomy and discrimination” in stent prices, the outrageous overpricing and exploitation in the marketing of drug-eluting stents,” said the letter to Jha.

The SJM further opposes suggestions to cap the price on the basis of a simple average of the price offered to hospitals.

“As can be seen through the NPPA’s calculations, such a price will not meet the purpose of ensuring affordability. Moreover, the industry-supplied data lacks authenticity and reflects corrupt marketing practices. Such a faulty methodology must not be used in deciding public policy,” it said.

Support for NPPA

In fact, the NPPA itself comes in for some support from the SJM, given that the pricing authority’s role was up for discussion at a top-level meeting involving the NITI Aayog.

The meeting sought to evaluate delinking price control from the list of essential medicines and the price regulator (NPPA). And the suggestion was that the NPPA in its present form be “wound up” and “deployed” within the Pharmaceuticals Department with “a new mandate”.

Mahajan said dismantling the NPPA runs contrary to the Centre’s Jan Aushadhi Yojna, where the effort is to provide affordable medicines to people. “In a democratic set-up, such checks and balances are required,” he said.